Edmond DE Rothschild Holding S.A. Takes Position in Natera, Inc. $NTRA

Edmond DE Rothschild Holding S.A. acquired a new stake in Natera, Inc. (NASDAQ:NTRA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,500 shares of the medical research company’s stock, valued at approximately $3,665,000.

Several other hedge funds also recently added to or reduced their stakes in NTRA. Csenge Advisory Group acquired a new stake in Natera during the second quarter worth $725,000. West Family Investments Inc. acquired a new position in shares of Natera in the 2nd quarter valued at $288,000. NewEdge Wealth LLC acquired a new position in shares of Natera in the 2nd quarter valued at $1,338,000. Eagle Health Investments LP purchased a new position in shares of Natera during the 2nd quarter worth $4,302,000. Finally, Danske Bank A S purchased a new position in shares of Natera during the 2nd quarter worth $16,640,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. Guggenheim boosted their price objective on shares of Natera from $290.00 to $360.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. The Goldman Sachs Group initiated coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 target price for the company. Stephens lifted their price target on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Citigroup lifted their price target on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Finally, Morgan Stanley restated an “overweight” rating and issued a $355.00 price objective on shares of Natera in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average price target of $319.38.

Insider Transactions at Natera

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the transaction, the chief executive officer owned 108,743 shares of the company’s stock, valued at approximately $24,035,465.29. This trade represents a 27.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 181,045 shares of company stock valued at $41,330,968. 5.05% of the stock is owned by corporate insiders.

Natera Trading Up 4.3%

NTRA opened at $325.07 on Thursday. The stock’s 50-day moving average price is $269.73 and its 200 day moving average price is $228.01. Natera, Inc. has a 12-month low of $156.71 and a 12-month high of $326.03. The firm has a market cap of $46.86 billion, a price-to-earnings ratio of -239.02 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera’s revenue was up 37.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.74) EPS. On average, research analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.